Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

James J. Harding, Sebastián Mondaca, Madappa N. Kundranda et al.|The Lancet Oncology|2023

Cited by 243